Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s10549-018-5055-9.pdf
Reference34 articles.
1. Sonnenblick A, Piccart M (2015) Adjuvant systemic therapy in breast cancer: quo vadis? Ann Oncol 26:1629–1634. https://doi.org/10.1093/annonc/mdv108
2. Senkus E, Kyriakides S, Ohno S et al (2015) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:v8–v30. https://doi.org/10.1093/annonc/mdv298
3. Denduluri N, Chavez-MacGregor M, Telli ML et al (2018) Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 36:2433–2443. https://doi.org/10.1200/JCO.2018.78.8604
4. Swain SM, Tang G, Geyer CE et al (2013) Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol 31:3197–3204. https://doi.org/10.1200/JCO.2012.48.1275
5. Steinherz LJ (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672. https://doi.org/10.1001/jama.1991.03470120074036
Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The population-level effects of omitting chemotherapy guided by a 21-gene expression assay in node-positive breast cancer: a simulation modeling study;BMC Cancer;2024-08-08
2. The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer—A Systematic Review and Meta-Analysis;Current Oncology;2024-08-03
3. Analysis of Chemotherapy Regimens on Survival Rate of Breast Cancer Patients;2024-01-23
4. Breast Cancer;Geriatric Medicine;2024
5. Breast Cancer;Geriatric Medicine;2023-12-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3